系统性红斑狼疮诊断新型血清生物标志物面板的发现
研究通过人类蛋白质组微阵列从15例SLE患者和5例健康志愿者血清中筛选候选自身抗体,并在107例SLE患者、94例健康志愿者和60例疾病对照中验证,筛选出抗RPLP2、抗SNRPC、抗PARP1及抗MAK16、抗RPL7A等自身抗体组合面板,ELISA在294例SLE患者和461例对照中确认抗MAK16性能,提示这些面板对SLE诊断及与其他主要风湿免疫病鉴别有前景。
要点
- 抗RPLP2、抗SNRPC、抗PARP1组合及抗RPLP2、抗PARP1、抗MAK16、抗RPL7A组合被选为诊断面板。
- ELISA在294例SLE患者和461例对照中验证了新发现的抗MAK16自身抗体。
- 抗PARP1水平与疾病活动度相关,抗RPLP2、抗MAK16、抗RPL7A水平与皮疹相关。
核心结论
- 本研究发现的新型自身抗体组合面板对SLE诊断及其他主要风湿免疫病的鉴别诊断具有应用前景。
研究设计与样本
- 研究先用人类蛋白质组微阵列分析15例SLE患者和5例健康志愿者血清以筛选候选自身抗体。
- 随后用聚焦阵列在107例SLE患者、94例健康志愿者和60例疾病对照中验证候选抗体。
- 采用逻辑回归推导并验证可区分SLE的自身抗体面板。
- 最后用ELISA在294例SLE患者和461例对照中验证新发现的抗MAK16自身抗体。
主要发现
- 共鉴定出31、11和18种自身抗体在SLE组中分别较健康志愿者、疾病对照及健康志愿者加疾病对照组的表达水平显著升高。
- 上述差异表达自身抗体中分别有25、7和13种为既往未报道的自身抗体。
- 选出的诊断面板包括抗RPLP2、抗SNRPC和抗PARP1组合,以及抗RPLP2、抗PARP1、抗MAK16和抗RPL7A组合。
- 新发现的抗MAK16自身抗体的性能通过ELISA得到确认。
- 观察到抗PARP1水平与疾病活动度相关,抗RPLP2、抗MAK16和抗RPL7A水平与皮疹相关。
临床怎么用
- 这些自身抗体面板有望用于SLE的诊断以及与其他主要风湿免疫病的鉴别诊断。
- 抗PARP1、抗RPLP2、抗MAK16和抗RPL7A水平与疾病活动度或皮疹相关,可为临床评估提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical diagnosis of SLE is currently challenging due to its heterogeneity. Many autoantibodies are associated with SLE and are considered potential diagnostic markers, but systematic screening and validation of such autoantibodies is lacking. This study aimed to systematically discover new autoantibodies that may be good biomarkers for use in SLE diagnosis. METHODS: Sera from 15 SLE patients and 5 healthy volunteers were analysed using human proteome microarrays to identify candidate SLE-related autoantibodies. The results were validated by screening of sera from 107 SLE patients, 94 healthy volunteers and 60 disease controls using focussed arrays comprised of autoantigens corresponding to the identified candidate antibodies. Logistic regression was used to derive and validate autoantibody panels that can discriminate SLE disease. Extensive ELISA screening of sera from 294 SLE patients and 461 controls was performed to validate one of the newly discovered autoantibodies. RESULTS: A total of 31, 11 and 18 autoantibodies were identified to be expressed at significantly higher levels in the SLE group than in the healthy volunteers, disease controls and healthy volunteers plus disease control groups, respectively, with 25, 7 and 13 of these differentially expressed autoantibodies being previously unreported. Diagnostic panels comprising anti-RPLP2, anti-SNRPC and anti-PARP1, and anti-RPLP2, anti-PARP1, anti-MAK16 and anti- RPL7A were selected. Performance of the newly discovered anti-MAK16 autoantibody was confirmed by ELISA. Some associations were seen with clinical characteristics of SLE patients, such as disease activity with the level of anti-PARP1 and rash with the level of anti-RPLP2, anti-MAK16 and anti- RPL7A. CONCLUSION: The combined autoantibody panels identified here show promise for the diagnosis of SLE and for differential diagnosis of other major rheumatic immune diseases.
引用
- Ling HZ, Xu SZ, Leng RX, et al. Discovery of new serum biomarker panels for systemic lupus erythematosus diagnosis. Rheumatology (Oxford). 2020. PMID: 31899518. doi:10.1093/rheumatology/kez634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。